Related references
Note: Only part of the references are listed.HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma
Stuart J. Gallagher et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential
Liqin Wang et al.
CELL (2018)
Harnessing BET Inhibitor Sensitivity Reveals AMIGO2 as a Melanoma Survival Gene
Barbara Fontanals-Cirera et al.
MOLECULAR CELL (2017)
An improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues
M. Ryan Corces et al.
NATURE METHODS (2017)
MicroRNA-125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathway
Lisa Koetz-Ploch et al.
PIGMENT CELL & MELANOMA RESEARCH (2017)
Tumor-associated B-cells induce tumor heterogeneity and therapy resistance
Rajasekharan Somasundaram et al.
NATURE COMMUNICATIONS (2017)
Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation
Chunying Song et al.
CANCER DISCOVERY (2017)
IGF-binding protein 2 is a candidate target of therapeutic potential in cancer
Xiaofeng Yao et al.
TUMOR BIOLOGY (2016)
Nfib Promotes Metastasis through a Widespread Increase in Chromatin Accessibility
Sarah K. Denny et al.
CELL (2016)
Essential role of HDAC6 in the regulation of PD-L1 in melanoma
M. Lienlaf et al.
MOLECULAR ONCOLOGY (2016)
Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma
Che-Hung Shen et al.
NATURE MEDICINE (2016)
An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation
George P. Souroullas et al.
NATURE MEDICINE (2016)
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance
Willy Hugo et al.
CELL (2015)
IGFBP-2: The dark horse in metabolism and cancer
V. C. Russo et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2015)
BET Bromodomain Inhibition Suppresses the Function of Hematopoietic Transcription Factors in Acute Myeloid Leukemia
Jae-Seok Roe et al.
MOLECULAR CELL (2015)
Histone Variant H2AZ2 Mediates Proliferation and Drug Sensitivity of Malignant Melanoma
Chiara Vardabasso et al.
MOLECULAR CELL (2015)
Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation
K. V. Woan et al.
MOLECULAR ONCOLOGY (2015)
A stress-induced early innate response causes multidrug tolerance in melanoma (vol 34, pg 4448, 2015)
D. Ravindran Menon et al.
ONCOGENE (2015)
The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors
Daniel Zingg et al.
NATURE COMMUNICATIONS (2015)
Epigenetic reprogramming by tumor-derived EZH2 gain-of-function mutations promotes aggressive 3D cell morphologies and enhances melanoma tumor growth
Anthony M. Barsotti et al.
ONCOTARGET (2015)
Chromatin-Remodelling Complex NURF Is Essential for Differentiation of Adult Melanocyte Stem Cells
Dana Koludrovic et al.
PLOS GENETICS (2015)
Transcription factor MITF and remodeller BRG1 define chromatin organisation at regulatory elements in melanoma cells
Patrick Laurette et al.
ELIFE (2015)
A chromatin modifier genetic screen identifies SIRT2 as a modulator of response to targeted therapies through the regulation of MEK kinase activity
P. K. Bajpe et al.
ONCOGENE (2015)
Proteomics analysis reveals IGFBP2 as a candidate diagnostic biomarker for heart failure
Matthieu Berry et al.
IJC METABOLIC & ENDOCRINE (2015)
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
Yang Liao et al.
BIOINFORMATICS (2014)
BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact
Helen Rizos et al.
CLINICAL CANCER RESEARCH (2014)
Tn5 transposase and tagmentation procedures for massively scaled sequencing projects
Simone Picelli et al.
GENOME RESEARCH (2014)
Targeting RAS-ERK signalling in cancer: promises and challenges
Ahmed A. Samatar et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells
Ophir Shalem et al.
SCIENCE (2014)
STAR: ultrafast universal RNA-seq aligner
Alexander Dobin et al.
BIOINFORMATICS (2013)
Overcoming Intrinsic Multidrug Resistance in Melanoma by Blocking the Mitochondrial Respiratory Chain of Slow-Cycling JARID1Bhigh Cells
Alexander Roesch et al.
CANCER CELL (2013)
BRD4 Sustains Melanoma Proliferation and Represents a New Target for Epigenetic Therapy
Miguel F. Segura et al.
CANCER RESEARCH (2013)
SIRT6 Recruits SNF2H to DNA Break Sites, Preventing Genomic Instability through Chromatin Remodeling
Debra Toiber et al.
MOLECULAR CELL (2013)
Tumor adaptation and resistance to RAF inhibitors
Piro Lito et al.
NATURE MEDICINE (2013)
The octamer is the major form of CENP-A nucleosomes at human centromeres
Dan Hasson et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2013)
RNA-Guided Human Genome Engineering via Cas9
Prashant Mali et al.
SCIENCE (2013)
Loss of 5-Hydroxymethylcytosine Is an Epigenetic Hallmark of Melanoma
Christine Guo Lian et al.
CELL (2012)
The Histone Deacetylase SIRT6 Is a Tumor Suppressor that Controls Cancer Metabolism
Carlos Sebastian et al.
CELL (2012)
The Deacetylase Sirt6 Activates the Acetyltransferase GCN5 and Suppresses Hepatic Gluconeogenesis
John E. Dominy et al.
MOLECULAR CELL (2012)
A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells
Kim J. Png et al.
NATURE (2012)
The sirtuin SIRT6 blocks IGF-Akt signaling and development of cardiac hypertrophy by targeting c-Jun
Nagalingam R. Sundaresan et al.
NATURE MEDICINE (2012)
Evidence for upregulation of Bim and the splicing factor SRp55 in melanoma cells from patients treated with selective BRAF inhibitors
Fritz Lai et al.
MELANOMA RESEARCH (2012)
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
MEK-Independent Survival of B-RAFV600E Melanoma Cells Selected for Resistance to Apoptosis Induced by the RAF Inhibitor PLX4720
Chen Chen Jiang et al.
CLINICAL CANCER RESEARCH (2011)
Kinetic Analysis Reveals the Fate of a MicroRNA following Target Regulation in Mammalian Cells
Alessia Baccarini et al.
CURRENT BIOLOGY (2011)
Sirtuins: Molecular Traffic Lights in the Crossroad of Oxidative Stress, Chromatin Remodeling, and Transcription
Ramkumar Rajendran et al.
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY (2011)
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikos I. Poulikakos et al.
NATURE (2011)
The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset
Craig J. Ceol et al.
NATURE (2011)
The SWOT of BRAF Inhibition in Melanoma: RAF Inhibitors, MEK Inhibitors or Both?
Moriah H. Nissan et al.
CURRENT ONCOLOGY REPORTS (2011)
Mammalian Sirtuins: Biological Insights and Disease Relevance
Marcia C. Haigis et al.
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE (2010)
Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
Jessie Villanueva et al.
CANCER CELL (2010)
Akt3-Mediated Resistance to Apoptosis in B-RAF-Targeted Melanoma Cells
Yongping Shao et al.
CANCER RESEARCH (2010)
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sreenath V. Sharma et al.
CELL (2010)
Plasma Insulin-Like Growth Factor-Binding Protein-2 Levels as Diagnostic and Prognostic Biomarker of Colorectal Cancer
Jyh-Ming Liou et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
The histone variant macroH2A suppresses melanoma progression through regulation of CDK8
Avnish Kapoor et al.
NATURE (2010)
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Gideon Bollag et al.
NATURE (2010)
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The sirtuin SIRT6 deacetylates H3 K56Ac in vivo to promote genomic stability
Bo Yang et al.
CELL CYCLE (2009)
Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-I receptor and insulin receptor
Mark J. Mulvihill et al.
FUTURE MEDICINAL CHEMISTRY (2009)
V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway
Christine A. Pratilas et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatin
Eriko Michishita et al.
NATURE (2008)
Current topics in melanoma
Jedd D. Wolchok et al.
CURRENT OPINION IN ONCOLOGY (2007)
Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells
Raoul Tibes et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Genomic instability and aging-like phenotype in the absence of mammalian SIRT6
R Mostoslavsky et al.
CELL (2006)
Expression of insulin-like growth factor-binding protein 2 in melanocytic lesions
HM Wang et al.
JOURNAL OF CUTANEOUS PATHOLOGY (2003)
Share Paper
